{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:10:32Z","timestamp":1772896232468,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"European Vaccine Initiative (EVI), the Dutch Directorate for International Collaboration(DGIS), the Irish Aid"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Plasmodium falciparum<\/jats:italic> apical membrane antigen 1 (PfAMA1) is a candidate malaria vaccine antigen expressed on merozoites and sporozoites. PfAMA1\u2019s polymorphic nature impacts vaccine-induced protection. To address polymorphism, three Diversity Covering (DiCo) protein sequences were designed and tested in a staggered phase Ia\/b trial. A cohort of malaria-naive adults received PfAMA1-DiCo adjuvanted with Alhydrogel\u00ae or GLA-SE and a cohort of malaria-exposed adults received placebo or GLA-SE adjuvanted PfAMA1 DiCo at weeks 0, 4 and 26. IgG and GIA levels measured 4 weeks after the third vaccination are similar in malaria-naive volunteers and placebo-immunised malaria-exposed adults, and have a similar breadth. Vaccination of malaria-exposed adults results in significant antibody level increases to the DiCo variants, but not to naturally occurring PfAMA1 variants. Moreover, GIA levels do not increase following vaccination. Future research will need to focus on stronger adjuvants and\/or adapted vaccination regimens, to induce potentially protective responses in the target group of the vaccine.<\/jats:p>","DOI":"10.1038\/s41541-021-00319-2","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T10:05:44Z","timestamp":1618394744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Accelerated phase Ia\/b evaluation of the malaria vaccine candidate PfAMA1 DiCo demonstrates broadening of humoral immune responses"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-6958","authenticated-orcid":false,"given":"Edmond J.","family":"Remarque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6808-1204","authenticated-orcid":false,"given":"Bart W.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Rodriguez Garcia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman","family":"Oostermeijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sodiomon B.","family":"Sirima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Issa","family":"Nebie Ouedraogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Kara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Houard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odile","family":"Leroy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens H. M.","family":"Kocken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"319_CR1","unstructured":"WHO. Malaria Vaccine Implementation Programme (MVIP), <https:\/\/www.who.int\/malaria\/media\/malaria-vaccine-implementation-qa\/en\/> (2020)."},{"key":"319_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-1-4939-9550-9_15","volume":"2013","author":"A Vijayan","year":"2019","unstructured":"Vijayan, A. & Chitnis, C. E. Development of blood stage malaria vaccines. Methods Mol. Biol. 2013, 199\u2013218 (2019).","journal-title":"Methods Mol. Biol."},{"key":"319_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.pt.2007.12.002","volume":"24","author":"EJ Remarque","year":"2008","unstructured":"Remarque, E. J., Faber, B. W., Kocken, C. H. & Thomas, A. W. Apical membrane antigen 1: a malaria vaccine candidate in review. Trends Parasitol. 24, 74\u201384 (2008).","journal-title":"Trends Parasitol."},{"key":"319_CR4","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1128\/IAI.00170-08","volume":"76","author":"EJ Remarque","year":"2008","unstructured":"Remarque, E. J., Faber, B. W., Kocken, C. H. & Thomas, A. W. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits. Infect. Immun. 76, 2660\u20132670 (2008).","journal-title":"Infect. Immun."},{"key":"319_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.pt.2015.12.007","volume":"32","author":"GE Weiss","year":"2016","unstructured":"Weiss, G. E., Crabb, B. S. & Gilson, P. R. Overlaying molecular and temporal aspects of malaria parasite invasion. Trends Parasitol. 32, 284\u2013295 (2016).","journal-title":"Trends Parasitol."},{"key":"319_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004670","volume":"11","author":"GE Weiss","year":"2015","unstructured":"Weiss, G. E. et al. Revealing the sequence and resulting cellular morphology of receptor-ligand interactions during Plasmodium falciparum invasion of erythrocytes. PLoS Pathog. 11, e1004670 (2015).","journal-title":"PLoS Pathog."},{"key":"319_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3552","volume":"4","author":"DY Bargieri","year":"2013","unstructured":"Bargieri, D. Y. et al. Apical membrane antigen 1 mediates apicomplexan parasite attachment but is dispensable for host cell invasion. Nat. Commun. 4, 2552 (2013).","journal-title":"Nat. Commun."},{"key":"319_CR8","doi-asserted-by":"publisher","first-page":"4471","DOI":"10.1128\/IAI.70.8.4471-4476.2002","volume":"70","author":"CH Kocken","year":"2002","unstructured":"Kocken, C. H. et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect. Immun. 70, 4471\u20134476 (2002).","journal-title":"Infect. Immun."},{"key":"319_CR9","doi-asserted-by":"publisher","first-page":"6948","DOI":"10.1128\/IAI.70.12.6948-6960.2002","volume":"70","author":"MC Kennedy","year":"2002","unstructured":"Kennedy, M. C. et al. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response. Infect. Immun. 70, 6948\u20136960 (2002).","journal-title":"Infect. Immun."},{"key":"319_CR10","doi-asserted-by":"publisher","first-page":"9490","DOI":"10.1074\/jbc.M311331200","volume":"279","author":"O Silvie","year":"2004","unstructured":"Silvie, O. et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 279, 9490\u20139496 (2004).","journal-title":"J. Biol. Chem."},{"key":"319_CR11","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","volume":"365","author":"MA Thera","year":"2011","unstructured":"Thera, M. A. et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365, 1004\u20131013 (2011).","journal-title":"N. Engl. J. Med."},{"key":"319_CR12","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1093\/infdis\/jiw039","volume":"213","author":"RO Payne","year":"2016","unstructured":"Payne, R. O. et al. Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum apical membrane antigen 1 vaccine, FMP2.1\/AS01. J. Infect. Dis. 213, 1743\u20131751 (2016).","journal-title":"J. Infect. Dis."},{"key":"319_CR13","doi-asserted-by":"publisher","first-page":"2ra5","DOI":"10.1126\/scitranslmed.3000257","volume":"1","author":"SL Takala","year":"2009","unstructured":"Takala, S. L. et al. Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development. Sci. Transl. Med. 1, 2ra5 (2009).","journal-title":"Sci. Transl. Med"},{"key":"319_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038898","volume":"7","author":"EJ Remarque","year":"2012","unstructured":"Remarque, E. J. et al. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naive adults. PLoS ONE 7, e38898 (2012).","journal-title":"PLoS ONE"},{"key":"319_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-10-182","volume":"10","author":"KA Kusi","year":"2011","unstructured":"Kusi, K. A. et al. Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT and Montanide ISA 51 in rhesus macaques. Malar. J. 10, 182 (2011).","journal-title":"Malar. J."},{"key":"319_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/14760584.2018.1411198","volume":"17","author":"KA Kusi","year":"2018","unstructured":"Kusi, K. A., Faber, B. W., Koopman, G. & Remarque, E. J. EDiP: the epitope dilution phenomenon. Lessons learnt from a malaria vaccine antigen and its applicability to polymorphic antigens. Expert Rev. Vaccines 17, 13\u201321 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"319_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015391","volume":"5","author":"KA Kusi","year":"2010","unstructured":"Kusi, K. A. et al. Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response. PLoS ONE 5, e15391 (2010).","journal-title":"PLoS ONE"},{"key":"319_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008110","volume":"4","author":"KA Kusi","year":"2009","unstructured":"Kusi, K. A., Faber, B. W., Thomas, A. W. & Remarque, E. J. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity. PLoS ONE 4, e8110 (2009).","journal-title":"PLoS ONE"},{"key":"319_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003840","volume":"9","author":"S Dutta","year":"2013","unstructured":"Dutta, S. et al. Overcoming antigenic diversity by enhancing the immunogenicity of conserved epitopes on the malaria vaccine candidate apical membrane antigen-1. PLoS Pathog. 9, e1003840 (2013).","journal-title":"PLoS Pathog."},{"key":"319_CR20","doi-asserted-by":"publisher","first-page":"6218","DOI":"10.1016\/j.vaccine.2017.09.027","volume":"35","author":"SB Sirima","year":"2017","unstructured":"Sirima, S. B. et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a\/1b, randomized, double-blind multi-centre trial. Vaccine 35, 6218\u20136227 (2017).","journal-title":"Vaccine"},{"key":"319_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003960","volume":"3","author":"M Roestenberg","year":"2008","unstructured":"Roestenberg, M. et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS ONE 3, e3960 (2008).","journal-title":"PLoS ONE"},{"key":"319_CR22","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1093\/cid\/ciy514","volume":"68","author":"V Steiner-Monard","year":"2019","unstructured":"Steiner-Monard, V. et al. The candidate blood-stage malaria vaccine P27A induces a robust humoral response in a fast track to the field phase 1 trial in exposed and nonexposed volunteers. Clin. Infect. Dis. 68, 466\u2013474 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"319_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020547","volume":"6","author":"M Mahdi Abdel Hamid","year":"2011","unstructured":"Mahdi Abdel Hamid, M. et al. Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT protects against blood-stage challenge in rhesus macaques. PLoS ONE 6, e20547 (2011).","journal-title":"PLoS ONE"},{"key":"319_CR24","doi-asserted-by":"publisher","first-page":"8776","DOI":"10.4049\/jimmunol.181.12.8776","volume":"181","author":"K Miura","year":"2008","unstructured":"Miura, K. et al. Comparison of biological activity of human anti-apical membrane antigen-1 antibodies induced by natural infection and vaccination. J. Immunol. 181, 8776\u20138783 (2008).","journal-title":"J. Immunol."},{"key":"319_CR25","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1128\/IAI.00960-09","volume":"78","author":"PD Crompton","year":"2010","unstructured":"Crompton, P. D. et al. In vitro growth-inhibitory activity and malaria risk in a cohort study in mali. Infect. Immun. 78, 737\u2013745 (2010).","journal-title":"Infect. Immun."},{"key":"319_CR26","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1046\/j.1365-2958.2000.02175.x","volume":"38","author":"T Triglia","year":"2000","unstructured":"Triglia, T. et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol. Microbiol. 38, 706\u2013718 (2000).","journal-title":"Mol. Microbiol."},{"key":"319_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.chom.2011.10.012","volume":"10","author":"D Giovannini","year":"2011","unstructured":"Giovannini, D. et al. Independent roles of apical membrane antigen 1 and rhoptry neck proteins during host cell invasion by apicomplexa. Cell Host Microbe 10, 591\u2013602 (2011).","journal-title":"Cell Host Microbe"},{"key":"319_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-016-1466-4","volume":"15","author":"MA Thera","year":"2016","unstructured":"Thera, M. A. et al. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25\u2013545]) in healthy Malian adults in Bandiagara. Malar. J. 15, 442 (2016).","journal-title":"Malar. J."},{"key":"319_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/14760584.2018.1435278","volume":"17","author":"MF Good","year":"2018","unstructured":"Good, M. F. & Miller, L. H. Interpreting challenge data from early phase malaria blood stage vaccine trials. Expert Rev. Vaccines 17, 189\u2013196 (2018).","journal-title":"Expert Rev. Vaccines"},{"key":"319_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1365-3024.1988.tb00241.x","volume":"10","author":"JA Deans","year":"1988","unstructured":"Deans, J. A. et al. Vaccination trials in rhesus monkeys with a minor, invariant, Plasmodium knowlesi 66 kD merozoite antigen. Parasite Immunol. 10, 535\u2013552 (1988).","journal-title":"Parasite Immunol."},{"key":"319_CR31","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1128\/IAI.73.6.3677-3685.2005","volume":"73","author":"EM Malkin","year":"2005","unstructured":"Malkin, E. M. et al. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria. Infect. Immun. 73, 3677\u20133685 (2005).","journal-title":"Infect. Immun."},{"key":"319_CR32","unstructured":"Kratz, A. et al. in Harrison\u2019s Principles of Internal Medicine. 2754\u20132769 (McGraw-Hill Education, 2015)."},{"key":"319_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jim.2012.02.008","volume":"378","author":"A Chauvat","year":"2012","unstructured":"Chauvat, A. et al. Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen. J. Immunol. Methods 378, 81\u201387 (2012).","journal-title":"J. Immunol. Methods"},{"key":"319_CR34","unstructured":"R Development Core Team. R: A LAnguage and Environment for Statistical Computing, <https:\/\/www.r-project.org\/> (R Development Core Team, 2020)."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00319-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00319-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:32:39Z","timestamp":1670023959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-021-00319-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["319"],"URL":"https:\/\/doi.org\/10.1038\/s41541-021-00319-2","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"14 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Three of the authors (E.J.R., B.W.F. and C.H.K.) are on a patent (Patent 8741305 (Jun 3, 2014)), \u201cProtein Composition for Inducing an Immune Response in a Vertebrate Comprising a Plurality of Protein Variants Covering the Heterogeneity of a Single Antigen, AMA1\u201d regarding the design of the proteins comprised in the product under investigation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}